Kiniksa Pharmaceuticals Ltd (KNSA)

NASDAQ
11.41
+0.18(+1.60%)
After Hours
11.41
0.00(0.00%)
- Real-time Data
  • Volume:
    227,706
  • Day's Range:
    10.76 - 11.47
  • 52 wk Range:
    7.36 - 17.19

KNSA Historical Data

Time Frame:
Daily
02/27/2023 - 03/25/2023
11.4111.2211.4710.76227.71K+1.60%
11.2311.1611.2710.85456.68K+1.08%
11.1111.3111.4411.10391.38K-1.86%
11.3211.1411.4511.14390.23K+1.80%
11.1211.3811.4511.02391.22K-2.54%
11.4111.5411.5611.131.21M-0.44%
11.4611.3311.6311.10349.64K+0.35%
11.4211.1511.5611.08514.08K+1.15%
11.2911.7912.0811.10763.29K-3.34%
11.6812.0612.3211.62892.31K-2.59%
11.9912.2612.3911.71471.89K-2.12%
12.2512.8313.1112.10532.50K-2.62%
12.5812.8012.9412.31338.98K-1.49%
12.7712.6412.9312.42350.57K+2.32%
12.4812.3012.4812.00384.84K+1.63%
12.2812.3712.4812.19339.23K-0.49%
12.3412.4312.7712.22391.21K-1.83%
12.5712.8713.3012.54370.34K-2.26%
12.8613.3614.1312.58456.07K-3.45%
13.3213.1413.5513.14214.99K+3.02%
Highest: 14.13Lowest: 10.76Difference: 3.37Average: 11.94Change %: -11.76
  • I'm surprised no activity there is little activity on this stock.
    0
    • The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
      0
      • Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
        0